Modifies provisions relating to alternative therapies

Summary

The bill lets patients with terminal, life‑threatening, or severely debilitating conditions obtain drugs, biologics, or devices that have passed Phase I trials but are not FDA‑approved. It sets eligibility criteria, lets manufacturers provide the products for free or at cost, and shields doctors and providers from license or legal actions for recommending or using them. Insurers and the state prison system are not required to cover the costs.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share